Sanreno Therapeutics

Founded in December 2021, SanReno Therapeutics is a clinical-stage biotech focused on kidney diseases and related therapeutic areas. SanReno’s founding investors and partners including Chinook Therapeutics, a leading player in kidney diseases, as well as Pivotal bioVenture Partners China and Frazier Healthcare Partners, both world renown life-science investors. SanReno is committed to the research and development, production and commercialization of drugs in kidney diseases and related therapeutic areas, looks forward to providing innovative clinical solutions to prolong the lives of patients and create a better quality of living for them. Currently, SanReno holds two core assets in the Greater China area and Singapore, including atrasentan (Phase III) and BION-1301 (Phase II).